Clinical trials: Digestive System
GERD
Study of the NDO Endoscopic Plication System For the Treatment of Symptomatic Gastroesophageal Reflux Disease
The purpose of this prospective, multicenter study was to evaluate the safety and efficacy of endoscopic full-thickness plication for the treatment of symptomatic gastroesophageal reflux.
- Trial name
- NCT00587522
- Testing
- NDO Full-thickness Plicator
- Where
- 7 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- NDO Surgical, Inc.
HER-2 Gene Amplification, Esophagus Cancer
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
- Conditions
- HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
- Trial name
- NCT01774851
- Testing
- MM-111, Paclitaxel, Trastuzumab
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- Merrimack Pharmaceuticals
Colon Cancer
Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer
Phase II study investigating the safety, tolerability and effect on disease reccurence of Foxy-5 as neo-adjuvant therapy in resected colon cancer patients treated with FOLFOX chemotherapy regimen.
- Trial name
- NeoFox (NCT03883802)
- Testing
- Foxy-5, FOLFOX regimen, Tumour resection (colon cancer surgery)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- WntResearch AB
Non-Small Cell Lung Cancer, Pancreatic Cancer
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT05919537
- Testing
- HMBD-001, Docetaxel, Nab-paclitaxel
- Where
- 5 sites in Australia
- Volunteers
- 68 people
- Sponsor
- Hummingbird Bioscience
Colorectal Cancer
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer.
- Trial name
- MRD (NCT05210283)
- Testing
- MRD
- Where
- 32 sites in United States, Canada
- Volunteers
- 1,017 people
- Sponsor
- Exact Sciences Corporation
Advanced Solid Tumors With and Without Brain Metastases
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
This is a phase 1, multi-centre, sequential cohort, open-label, dose-escalation study of the safety, tolerability, and PK of ANG1005 in patients with solid tumors (with or without brain metastases).
- Trial name
- NCT00539383
- Testing
- ANG1005
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Angiochem Inc
Hepatitis B, Hepatitis B Infection
A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites
A prospective cross-sectional study in which surgically non-invasive sample-taking is done only for the purpose of the study. Capillary (fingerstick) whole blood and EDTA venipuncture whole blood are collected by a healthcare…
- Trial name
- NCT06368466
- Testing
- iStatis HBsAg Test
- Where
- Australia
- Volunteers
- 175 people
- Sponsor
- bioLytical Laboratories
Gastric Cancer, Gastroesophageal Junction Cancer
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
This study will evaluate overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.
- Trial name
- NCT01813253
- Testing
- Irinotecan, Nimotuzumab
- Where
- 37 sites in Japan, South Korea and 1 more
- Volunteers
- 400 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
GERD
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.
- Trial name
- MAESTRO (NCT00444275)
- Testing
- esomeprazole (Nexium®), Xolaam®
- Where
- France
- Volunteers
- 3,029 people
- Sponsor
- AstraZeneca
HepatoCellular Carcinoma
CHARM Hepatocellular Carcinoma MEA Study
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third reason for cancer-related death worldwide.
- Trial name
- NCT07650773
- Where
- 17 sites in Egypt, Kuwait and 5 more
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Pharmacokinetics, Cardiodynamic ECG
A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate.
- Conditions
- Pharmacokinetics, Cardiodynamic ECG, Safety, and Tolerability, GERD
- Trial name
- NCT05469854
- Testing
- Linaprazan glurate
- Where
- Sweden
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Intussusception (IS), Rotavirus Vaccines
Intussusception Surveillance After Rotarix Introduction in Mexico
GSK Biologicals' rotavirus vaccine, Rotarix™ has been recommended for universal use targeting infants through the Expanded Program on Immunization (EPI) in Mexico.
- Trial name
- NCT00595205
- Testing
- Hospital log review.
- Where
- Mexico
- Volunteers
- 786 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of chronic hepatitis B virus (HBV) infection (CHB).
- Trial name
- NCT05867056
- Testing
- IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD
- Where
- 15 sites in United States, Australia and 7 more
- Sponsor
- Immunocore Ltd
Advanced Solid Tumors
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
- Trial name
- NCT00603356
- Testing
- OSI-930 and erlotinib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Effect of Probiotic Supplement on Bowel Function
The purpose of this study is to analyse the effect of probiotic supplement on symptoms of irritable bowel syndrome.
- Trial name
- IBS2 (NCT01475929)
- Testing
- Probiotic supplement
- Where
- Finland
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Danisco
Acute-on-Chronic Liver Failure (ACLF), Liver Cirrhosis
A Novel Extracorporeal Liver Support Therapy In ALCF and to Evaluate the Efficacy of DIALIVE 2.0, a Liver Dialysis Device.
This study is intended to demonstrate the efficacy and safety of the DIALIVE Liver Dialysis Device when incorporated into the standard management plan for participants with A-TANGO ACLF grade 2-4.
- Trial name
- NCT07347275
- Testing
- Standard of Care (Investigator Choice), DIALIVE 2.0 liver dialysis Device plus available Standard of Care
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Yaqrit Ltd
Malnutrition, Cancer
Impact of a New Plant-based High-energy Oral Nutritional Supplement on Nutritional Outcomes in Malnourished Patients
This study aims to compare nutritional outcomes in terms of percentage of weight gain between a new planted-based high-energy ONS and a standard high-energy ONS with animal protein (cow's mil protein) in patients at malnutrition…
- Conditions
- Malnutrition, Cancer, Inflammatory Bowel Diseases, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06055543
- Testing
- Fortimel
- Where
- 6 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Danone Specialized Nutrition
Ulcerative Colitis (UC)
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had…
- Trial name
- U-ACTIVATE (NCT03006068)
- Testing
- Upadacitinib (ABT-494)
- Where
- 492 sites in United States, Argentina and 44 more
- Volunteers
- 950 people
- Sponsor
- AbbVie
Gastrointestinal Stromal Tumor, Sarcoma
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Conditions
- Gastrointestinal Stromal Tumor, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00005874
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease
A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.
The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.
- Trial name
- NCT00220818
- Testing
- Lansoprazole
- Volunteers
- 24 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.